To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
GH Research starts trading on NASDAQ
GH Research, a biopharmaceutical company that treats psychiatric and neurological disorders, has raised about $160 million for its IPO after pricing its 10 million shares at $16 per share.
